Skip to main content
. 2023 Nov 10;11(22):2940. doi: 10.3390/healthcare11222940

Table 1.

Baseline characteristics of the study population.

Subject Controls
(n = 98)
PVCs
(n = 94)
p Value
Age (yrs) 50.84 ± 9.41 49.83 ±13.63 0.551
Male (n,%) 55 (56.1) 47 (50.0) 0.395
Height (cm) 166.54 ± 7.58 165.97 ± 6.89 0.590
Weight (kg) 69.39 ± 13.38 65.92 ± 10.95 0.052
Body mass index (kg/m2) 24.89 ± 3.65 23.87 ± 3.36 0.050
Smoking (n,%) 15 (15.3) 11 (11.8) 0.484
CAD (n,%) 18 (18.1) 16 (17.0) 0.156
ACS (n,%) 10 (10.2) 9 (9.6) 0.892
Number of lesional coronary artery 0.771
1-vessel CAD (n,%) 6 (6.1) 8 (8.5)
2-vessel CAD (n,%) 4 (4.1) 3 (3.1)
3-vessel CAD (n,%) 8 (8.2) 5 (5.3)
Gensini score 16.77 ± 11.45 19.20 ± 17.01 0.672
Hypertension (n,%) 33 (33.7) 47 (50.0) 0.071
Hyperlipidemia (n,%) 23 (23.5) 24 (25.5) 0.997
Diabetes (n,%) 12 (12.2) 14 (14.9) 0.758
Medication use
Beta-blocker (n,%) 44 (44.9) 37 (37.8) 0.204
Calcium channel blocker (n,%) 19 (19.4) 28 (28.6) 0.178
Laboratories
NT-proBNP (pg/mL) 35.5 (49.5) 62.1 (83.0) 0.044
cTnI (ng/mL) 5.32 ± 14.30 4.24 ± 6.81 0.509
eGFR (mL/min/1.73 m²) 91.86 ± 12.83 89.34 ± 20.97 0.532

Comparison between the two groups conducted using the Mann–Whitney U test. Abbreviations: PVC, premature ventricular complex; CAD, coronary artery disease; ACS, acute coronary syndrome; NT-proBNP, N-terminal pro-brain natriuretic peptide.